Prognosis

A mesothelioma diagnosis comes with many important questions. Perhaps the most crucial question is – what is the prognosis? In fact, the prognosis of mesothelioma varies depending on a number of variables. These variables include:

1. The patient – their age, biology, and state of health
2. The cancer – has the mesothelioma spread or is it localized when it is diagnosed and what is the cell type
3. The treatment or treatments selected
4. The expertise of the treatment team (doctors and other clinicians)

The Patient’s Health

A patient’s general state of health is an important prognostic factor in fighting any disease and mesothelioma is no exception. In addition, a patient’s biology or physiology also plays a role. For example, will chemotherapy work or can it be tolerated? Does the patient have a heart condition so that surgery is not an option? How will the patient’s biology interact with the treatment? The answers to these questions can all play a role in the prognosis.

The Cancer

The spread or lack of spread of the cancer is also an important factor. If mesothelioma is localized it can be easier to treat. In fact, surgery is usually only an option if the cancer has not metastasized. If it has spread then treatment options may be more limited. In addition, there are three cell types of mesothelioma – epithelioid, biphasic, and sacramatoid. The first, epithelioid, often has the best prognosis of the three.

The Treatment

The treatment or therapies selected is also important. Patients can select from conventional therapies (radiation, chemo, and surgery), clinical trials or integrative or alternative modalities. Not every therapy works in every patient. There is an important connection between a person’s physiology, cancer and the treatments selected. The interchange or intersection of these three factors often dictate what the treatment outcome and prognosis will be. Unfortunately, it is often difficult to predict because how a tumor or a treatment acts in a patient’s body is often not known until after the fact.

The Doctors’ Expertise

The last factor is the expertise of your doctors or licensed care givers. How these people do their jobs can be a key factor in prognosis. Are the surgeons experienced with mesothelioma? For example, what is their mortality rate for surgery? The smallest rate bodes better than the highest rate. Also, what options can these treaters suggest? Do they only offer chemo or can they offer a wide range of different modalities and treatment options. All these factors play a role in the prognosis of mesothelioma.

Below are some more details about the prognosis for mesothelioma.

Prognosis of Pleural Mesothelioma

The prognosis of pleural mesothelioma with standard treatment is typically not great.   Median overall survival is a little over a year.  However, there are a number of factors that affect prognosis.

A number of studies have been performed over the years to determine what treatments are optimum for mesothelioma and what factors lead to a better prognosis. Below, we report on several of these.

In a September 2016 Austrian study, a total of 210 patients with malignant pleural mesothelioma were followed.

• 167 (79.5%) were men and 43 (20.5%) were women
• The average age was 67 at the time of diagnosis
• Asbestos exposure was confirmed in 109 (69.4%) patients
• The majority of patients had epithelioid cell type (67.2%)
• Sarcomatoid comprised 16 (7.6%)
• Biphasic was found in 28 patients (13.3%)
• In 25 patients, the cell type was not specified

Data about survival was available for 185 patients. The study found:

• Median overall survival was 19.1 months.
• Pleural mesothelioma patients with early-stage disease (stages I, II) had an overall survival of 26.4 months.
• Pleural mesothelioma patients with late-stage disease (stages III, IV) had an overall survival of 13.0 months .
• Patients with epithelioid cell type had overall survival of 25.1 months.
• Patients with sarcomatoid or biphasic cell type had overall survival of 10.2 months.
• There was no survival difference between males and females.
• There was no survival difference between patients below or above the age of 65 years.
• Survival was significantly better in patients undergoing surgery. However, these patients were significantly younger, had earlier-stage disease, better performance status, and more often had epithelioid subtype.

The study concluded that factors that indicated a better prognosis included: higher Karnofsky score, earlier stage disease, epithelioid cell type, and surgery within multimodality treatment.

• Management of malignant pleural mesothelioma – part 3 : Data from the Austrian Mesothelioma Interest Group (AMIG) database. Klikovits T, et al., Wien Klin Wochenschr. 2016 Sep;128(17-18):627-34.

Prognosis of Peritoneal Mesothelioma

The prognosis of peritoneal mesothelioma has become much better with the advent of surgery and HIPEC.  The following studies illustrate the improvements in prognosis over the last several years.

Peritoneal Mesothelioma Prognosis with Chemotherapy

In a 2011 Greek Study, chemotherapy was used to treat peritoneal mesothelioma patients.  Six patients with peritoneal mesothelioma were treated with 6 cycles of pemetrexed (500 mg/m2) and cisplatin (75 mg/m2). Chemotherapy was administered on an outpatient basis every 3 weeks. The estimated median overall survival was 24 months.

• Systemic chemotherapy with pemetrexed and cisplatin for malignant peritoneal mesothelioma: a single institution experience. Lainakis G, et al., Tumori. 2011 Jan-Feb;97(1):25-9.

Peritoneal Mesothelioma Prognosis with HIPEC

An April 2014 United States Study examined 65 patients with pleural mesothelioma who underwent surgery and HIPEC (hyperthermic intraperitoneal chemoperfusion) between 2001 and 2010.

What is HIPEC for Mesothelioma?

HIPEC is where heated chemotherapy is used to bath the surgical cavity putting the chemo in direct contact where the tumor cells remain.  The study found that overall mesothelioma survival was 46.2 months.  The study also found that although survival was better, there were side effects associated with this treatment approach that included:

• Six percent of the patients died within 60 days.
• Of the 65 patients, 91 % were admitted to the intensive care unit (ICU) postoperatively, with median hospital length of 12 days.
• A total of 12 patients (18 %) underwent reoperation: four patients (33 %) for enteric leak, 1 patient (8 %) for an intra-abdominal abscess, and seven patients (58%) for other reasons.

Factors that contributed to a poor prognosis included:

• Older patient
• More widespread tumors
• More aggressive cell type
• Incomplete surgery
• Post-operative infection

The study concluded that better prognosis is associated with patients who have the epithelioid cell type, lower volume of tumor, and more effective surgery (most tumor removed).

• Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Magge D., et al., Ann Surg Oncol. 2014 Apr;21(4):1159-65.

Next: Treatment

Related Posts

Quality of Life for Mesothelioma Patients Hinges on Activity and Nutrition- Muscle mass and nutrition can have a direct impact on quality of life for mesothelioma patients. That’s the finding of an Australian study of sixty-one men and women with malignant pleural mesothelioma. Researchers say the quality of life for mesothelioma patients was compromised by lower muscle mass or malnutrition. It is a wake-up call for mesothelioma patients to stay active and eat well for the best outcomes. Impacts on Quality of Life for Mesothelioma Patients Pleural mesothelioma is an incurable cancer. Even with the best mesothelioma treatments, most patients still face a grim prognosis. But there is evidence that good self-care may help. Previous studies have shown that patients with the best nutritional status often have longer mesothelioma survival. Nutritional … Continue reading Quality of Life for Mesothelioma Patients Hinges on Activity and Nutrition »

New Research Reveals Gene Signature for Mesothelioma- Researchers in China say they have come up with a three-gene signature for mesothelioma. The gene signature may help doctors determine mesothelioma prognosis and plan treatment. Pleural mesothelioma is challenging to diagnose and even harder to treat. Many patients do not receive a diagnosis until the disease is in an advanced stage. The new study finds that the gene signature for mesothelioma is “significantly associated”  with overall survival in people with the pleural variety. Testing a Gene Signature for Mesothelioma Genes play an important role in the development and progression of cancers like mesothelioma. The Chinese researchers started by searching for other studies on  mesothelioma prognosis and genes. “The lack of relevant search results indicated that no gene prognostic signatures … Continue reading New Research Reveals Gene Signature for Mesothelioma »

Research Highlights Connection Between BDNF and Mesothelioma Survival- French scientists say there is a clear connection between a biomarker called BDNF and mesothelioma survival. The research may open the door to improved mesothelioma diagnosis, prognosis, and treatment. BDNF stands for brain-derived neurotrophic factor. It is a protein found in the brain and other tissues. In a new published study, researchers at the University of Nantes found that mesothelioma patients had higher BDNF levels than people with other cancers. Mesothelioma patients with the highest BDNF levels had the shortest mesothelioma survival. Linking BDNF and Mesothelioma Survival A biomarker is a substance that can be used to show the presence of disease. BDNF is a soluble mesothelioma biomarker. Soluble biomarkers are in body fluid and can be collected without a … Continue reading Research Highlights Connection Between BDNF and Mesothelioma Survival »

Early Detection of Mesothelioma with MicroRNAs- A new study appears to contradict some of what scientists thought they knew about early detection of mesothelioma. Malignant mesothelioma is a rare but highly aggressive cancer. It usually happens because of past asbestos exposure. Early detection of mesothelioma is key to improving survival. But it is notoriously hard to make a mesothelioma diagnosis. Many patients who have mesothelioma do not even know it until the cancer is in its advanced stage. As a result, most do not live more than a year. Some studies have suggested that tiny, non-coding bits of RNA could help doctors detect mesothelioma earlier. But new research in Germany brings that idea into question. Biomarkers for Early Detection of Mesothelioma MicroRNAs (miRNAs) play an important … Continue reading Early Detection of Mesothelioma with MicroRNAs »

Talc Pleurodesis Patients Need Alternate PET/CT Scan for Mesothelioma- Certain patients may get more benefit out of an alternate type of PET/CT scan for mesothelioma. Positron emission tomography (PET) is a common tool for diagnosing mesothelioma. It is also used to monitor the effectiveness of mesothelioma treatments. Doctors often combine PET with computed tomography (CT) for an even clearer picture of mesothelioma progression. Typically, a PET/CT scan for mesothelioma involves injection of a tracer called FDG (fluorodeoxyglucose). But it turns out that PET/CT scans with this tracer do not work well for all mesothelioma patients. A new Japanese study suggests that mesothelioma patients who have had a procedure called talc pleurodesis should consider a different kind of PET/CT scan instead. How Does Talc Pleurodesis Impact PET/CT Scan for Mesothelioma? … Continue reading Talc Pleurodesis Patients Need Alternate PET/CT Scan for Mesothelioma »

Nutritional Status of Mesothelioma Patients and Prognosis- The nutritional status of mesothelioma patients could impact their treatment outcomes. That is the conclusion of a new Chinese study. The study focused on patients with peritoneal mesothelioma. Peritoneal mesothelioma is a cancer that grows on the abdominal lining. About a fifth of mesothelioma patients have this type. Researchers at Cangzhou Central Hospital measured the nutritional status of mesothelioma patients with a tool called the Controlling Nutritional Status (CONUT) score. When they compared the scores with patients’ survival rates, they found that those with worse scores did not live as long. Measuring Nutritional Status of Mesothelioma Patients with CONUT CONUT is a computer-based tool. It calculates the nutritional status of mesothelioma patients based on laboratory information. Lab values considered by … Continue reading Nutritional Status of Mesothelioma Patients and Prognosis »

Who Survives Mesothelioma and Why?- A new study of National Cancer Institute data aims to better understand who survives mesothelioma and why. Malignant mesothelioma is a highly aggressive cancer of internal membranes. Very few people diagnosed with mesothelioma live longer than 18 months. But researchers around the world are working to change those odds. One important step is to look at the characteristics of those who live longest with the asbestos cancer. NCI Data Shows Who Survives Mesothelioma Scientists at Mount Sinai Medical Center in New York turned to the National Cancer Institute database to get a better picture of who survives mesothelioma. The database contains information reported by mesothelioma doctors from around the country. It includes information about the ages, gender, lifestyle, mesothelioma type, … Continue reading Who Survives Mesothelioma and Why? »

Ginsburg’s Recovery Shows Value of Healthy Lifestyle for Mesothelioma Survival- Justice Ruth Bader Ginsburg’s successful lung cancer surgery illustrates the value of healthy lifestyle for mesothelioma survival. Although Ginsburg did not have mesothelioma, people battling the asbestos cancer would do well to pay attention. The 85-year-old Supreme Court justice recently had two nodules removed from her left lung. Her lung cancer was in an early stage. Doctors say they were able to remove all signs of cancer and Ginsburg is now recovering at home. Ginsburg’s Regular Exercise Routine Justice Ginsburg has survived cancer twice before. She had colon cancer in 1999 and pancreatic cancer in 2009. In both cases, she bounced back quickly. She did not miss a day on the bench. Ginsburg is known for her healthy lifestyle. She eats … Continue reading Ginsburg’s Recovery Shows Value of Healthy Lifestyle for Mesothelioma Survival »

Mesothelioma Staging May be Easier with New Approach- Japanese researchers have introduced a new approach to mesothelioma staging. The new system may make it easier to plan treatment and predict mesothelioma prognosis. Tumor staging is a system for measuring how far cancer has spread in the body. It is based on what doctors know about how cancer develops and grows. The more places mesothelioma cells are, the more difficult the case is to treat. The TNM Staging System is the most widely used system for mesothelioma staging. The American Joint Committee on Cancer established the system. In the TNM system, T stands for the size of the primary mesothelioma tumor. N stands for the spread of cancer to the lymph nodes. M is about cancer spread to other … Continue reading Mesothelioma Staging May be Easier with New Approach »

Combination Therapy with Mesothelioma Surgery Leads to Longer Survival- A new study finds almost a quarter of people who had combination therapy with mesothelioma surgery were still alive five years later. The study was published in the European Journal of Cardio-Thoracic Surgery. Researchers at University Hospitals KU Leuven in Belgium studied nearly 200 mesothelioma patients from 2003 to 2014. Many people do not live beyond about 18 months after a mesothelioma diagnosis. But the Belgian team says, for the right patients, there is a way to improve the odds. They say combination therapy with radical mesothelioma surgery offers a 1 in 4 chance of surviving for 5 years or more. Two Types of Mesothelioma Surgery There are two major schools of thought about mesothelioma surgery. Some surgeons say it … Continue reading Combination Therapy with Mesothelioma Surgery Leads to Longer Survival »